Thomas H Beck leads the New York IP group, and focuses on complex chemical and pharmaceutical litigation matters. In 2012, Mr Beck’s team won a two-week jury trial for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma drug Xopenex (levalbuterol), winning lost profits, reasonable royalty and a finding of wilful infringement. The National Law Journal listed that verdict in the top 100 jury verdicts for 2012, and it was also in the top 20 IP jury awards for 2012.
He is also lead counsel for Sunovion in Hatch-Waxman litigation against Actavis concerning Xopenex HFA. The case was tried in November 2014, and a decision is expected in June 2015. His team prevailed in the Markman rulings in March and June 2014, as well as in the Court's pretrial rulings.
He was recently lead counsel for Noven Pharmaceuticals in Hatch-Waxman litigation against Watson concerning the Daytrana transdermal patch treatment for ADHD, which settled favourably on the eve of trial.
Mr Beck was lead counsel for ConvaTec in litigation concerning medical devices providing negative pressure wound therapy, and for LSI in litigation against Xilinx involving numerous patents relating to programmable field gate arrays and related circuits. Mr Beck has also led several successful multimillion-dollar mediation and arbitration efforts, including Marvell v Agere which involved 802.11 wifi networks.
Mr Beck received his JD from Harvard Law School in 1979 and his BS (with honours) from North Dakota State University in 1975.
This biography is an extract from Who's Who Legal: Patents which can be purchased from our Shop.
Thomas Beck leads the New York intellectual property litigation group, and focuses on complex chemical and pharmaceutical patent litigation matters. Notable results include a two-week jury trial win for Sunovion in Hatch-Waxman litigation against Mylan concerning the asthma drug Xopenex (levalbuterol), winning lost profits, plus a reasonable royalty and a jury finding of willful infringement. He has counselled clients regarding drug analogues, fusion proteins, recombinant DNA techniques and analytical methods and medical device technologies.
Tom also regularly presents on Hatch-Waxman issues at the ACI Paragraph IV litigation conferences in New York in 2014, 2011, 2008 and 2007, and at the Momentum Par. IV conference in NY in 2013.
WWL says: A veteran trial lawyers with a “first rate” practice
This biography is an extract from Who's Who Legal: Life Sciences which can be purchased from our Shop.
It is not possible to buy entry into any Who's Who Legal publication
Nominees have been selected based upon comprehensive, independent survey work with both general counsel and private practice lawyers worldwide. Only specialists who have met independent international research criteria are listed.